CH577461A5 - - Google Patents

Info

Publication number
CH577461A5
CH577461A5 CH690373A CH690373A CH577461A5 CH 577461 A5 CH577461 A5 CH 577461A5 CH 690373 A CH690373 A CH 690373A CH 690373 A CH690373 A CH 690373A CH 577461 A5 CH577461 A5 CH 577461A5
Authority
CH
Switzerland
Application number
CH690373A
Original Assignee
Robins Co Inc A H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robins Co Inc A H filed Critical Robins Co Inc A H
Publication of CH577461A5 publication Critical patent/CH577461A5/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH690373A 1975-08-13 1973-05-15 CH577461A5 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/604,371 US4045576A (en) 1975-08-13 1975-08-13 Anti-inflammatory methods using 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof and the compounds

Publications (1)

Publication Number Publication Date
CH577461A5 true CH577461A5 (nl) 1976-07-15

Family

ID=24419335

Family Applications (1)

Application Number Title Priority Date Filing Date
CH690373A CH577461A5 (nl) 1975-08-13 1973-05-15

Country Status (15)

Country Link
US (3) US4045576A (nl)
JP (3) JPS523381B2 (nl)
AT (2) AT329542B (nl)
AU (1) AU530940B2 (nl)
BE (2) BE799611A (nl)
CA (2) CA1012979A (nl)
CH (1) CH577461A5 (nl)
DE (2) DE2324768C2 (nl)
ES (1) ES446625A1 (nl)
FR (1) FR2184934B1 (nl)
GB (2) GB1432576A (nl)
MX (1) MX4035E (nl)
NL (1) NL183722C (nl)
PH (2) PH12656A (nl)
SE (1) SE400966B (nl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
FR2366015A1 (fr) * 1975-11-05 1978-04-28 Robins Co Inc A H Nouveaux acides amino-2 benzoyl-3 (5 et 6) phenylacetiques et leurs esters et sels de metaux alcalins, utiles notamment comme anti-inflammatoires, et leur procede de preparation
US4221716A (en) * 1979-02-16 1980-09-09 A. H. Robins Company, Inc. Intermediate and process for the preparation of 7-acylindolin-2-ones
EP0089426B1 (en) * 1979-07-12 1986-06-11 A.H. Robins Company, Incorporated 2-amino-6-biphenylacetic acids
IL60444A (en) * 1979-08-01 1985-03-31 Robins Co Inc A H 2-amino-3-(alkylthiobenzoyl)-phenylacetic acid derivatives and pharmaceutical compositions containing them
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
JPS6019753A (ja) * 1983-07-13 1985-01-31 Shionogi & Co Ltd オルト−(モノ置換アミノ)フエニルイミン類およびその製造法
JPS6026586U (ja) * 1983-07-29 1985-02-22 日本軽金属株式会社 改装サッシ窓における隙間閉塞装置
SE8400239D0 (sv) * 1984-01-19 1984-01-19 Pharmacia Ab Nya arylettiksyraderivat
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US4782089A (en) * 1986-08-26 1988-11-01 A. H. Robins Company, Incorporated 2-amino-3-aroyl-gamma-oxobenzenebutanoic acids and esters
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5179119A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 1,3-dihydro-1-(pyridinylamino)-2H-indol-1-ones and intermediates for the preparation thereof
AU659106B2 (en) * 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted phenyl and pyridyl amino carboxylates
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
CA2288125A1 (en) * 1997-04-28 1998-11-05 Medical Information Services, Inc. Process for producing ketoprofen and 5-benzoyl-3-methyl-2-indolinone
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US7186745B2 (en) * 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
US6646003B2 (en) 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
US6692772B2 (en) * 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
JP2005525408A (ja) * 2002-05-03 2005-08-25 アルコン,インコーポレイテッド アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法
JP4500261B2 (ja) 2003-01-21 2010-07-14 千寿製薬株式会社 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
CA2666143A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
MX2009003876A (es) * 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
US20090076150A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched bromfenac
US20110054031A1 (en) * 2008-02-21 2011-03-03 Ista Pharmaceuticals, Inc. Ophthalmic NSAIDS as Adjuvants
KR101286323B1 (ko) 2008-10-17 2013-07-15 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2655346B1 (de) * 2010-12-21 2015-01-21 Bayer Intellectual Property GmbH Verfahren zur herstellung von 2-(triazinylcarbonyl)sulfonaniliden
CA2890182C (en) 2012-11-19 2020-10-06 Bausch & Lomb Incorporated Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
EA201591910A1 (ru) 2013-06-19 2016-05-31 Сентисс Рисерч Центр Стабильный раствор бромфенака
US20170000889A1 (en) 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104974057B (zh) * 2014-04-08 2018-05-18 天津金耀集团有限公司 一种溴芬酸钠的制备方法和重要中间体
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN104693019B (zh) * 2015-02-06 2017-02-01 宁波九胜创新医药科技有限公司 一种2,5‑二溴苯乙酸的制备方法
CN106278917B (zh) * 2016-08-12 2018-05-08 合肥久诺医药科技有限公司 一种溴芬酸钠降解杂质标准品的合成方法
CN106278918B (zh) * 2016-08-12 2018-05-11 合肥久诺医药科技有限公司 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法
US11174327B2 (en) 2017-06-30 2021-11-16 Kuraray Co., Ltd. Method for producing modified polyvinyl alcohol resin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (nl) * 1967-07-31 1971-03-24
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror

Also Published As

Publication number Publication date
NL7306833A (nl) 1973-11-20
NL183722C (nl) 1989-01-02
GB1432576A (en) 1976-04-22
DE2636582A1 (de) 1977-02-24
CA1012979A (en) 1977-06-28
NL183722B (nl) 1988-08-01
ATA977475A (de) 1978-05-15
JPS5223052A (en) 1977-02-21
JPS5726585B2 (nl) 1982-06-05
US4182774A (en) 1980-01-08
AT347433B (de) 1978-12-27
US4045576A (en) 1977-08-30
BE799611A (fr) 1973-09-17
AU530940B2 (en) 1983-08-04
GB1521097A (en) 1978-08-09
ES446625A1 (es) 1977-06-01
DE2324768A1 (de) 1973-11-29
CA1087205A (en) 1980-10-07
PH15112A (en) 1982-08-10
AU5584673A (en) 1974-11-21
JPS55349A (en) 1980-01-05
MX4035E (es) 1981-11-18
JPS523381B2 (nl) 1977-01-27
FR2184934A1 (nl) 1973-12-28
PH12656A (en) 1979-07-11
DE2324768C2 (de) 1985-08-14
ATA429873A (de) 1975-08-15
AT329542B (de) 1976-05-10
SE400966B (sv) 1978-04-17
BE837154A (fr) 1976-04-16
US4126635A (en) 1978-11-21
FR2184934B1 (nl) 1976-11-05
AU6181480A (en) 1981-01-08
JPS4941349A (nl) 1974-04-18
DE2636582C2 (de) 1986-03-27

Similar Documents

Publication Publication Date Title
AR201758A1 (nl)
AU476761B2 (nl)
AU465372B2 (nl)
AR201235Q (nl)
AR201231Q (nl)
FR2184934A1 (nl)
AU474593B2 (nl)
AU474511B2 (nl)
AU474838B2 (nl)
AU471343B2 (nl)
AU465453B2 (nl)
AU465434B2 (nl)
AU450229B2 (nl)
AU476714B2 (nl)
AR201229Q (nl)
AU466283B2 (nl)
AU476696B2 (nl)
AU472848B2 (nl)
AR199451A1 (nl)
AU477823B2 (nl)
AR200885A1 (nl)
AR195311A1 (nl)
AR200256A1 (nl)
AR201432A1 (nl)
AU477824B2 (nl)

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: A. H. ROBINS COMPANY, INCORPORATED (A DELAWARE COR

PUE Assignment

Owner name: AHP SUBSIDIARY (9) CORPORATION

PL Patent ceased